Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S L Soignet

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The Oncologist|May 2, 2001
Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemiaS L Soignet
The Oncologist|May 2, 2001
Risk/benefit profile of arsenic trioxideD M Rust, S L Soignet
Cancer Chemotherapy and Pharmacology|September 29, 1999
Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemiaS L Soignet, W P Tong, S Hirschfeld, et al.
Blood|August 15, 2000
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesisG J Roboz, S Dias, G Lam, et al.
Leukemia|October 10, 1998
Clinical study of 9-cis retinoic acid (LGD1057) in acute promyelocytic leukemiaS L Soignet, F Benedetti, A Fleischauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2000
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxideL H Camacho, S L Soignet, S Chanel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550)S L Soignet, V A Miller, D G Pfister, et al.
The New England Journal of Medicine|November 5, 1998
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxideS L Soignet, P Maslak, Z G Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2001
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemiaS L Soignet, S R Frankel, D Douer, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Oncologist|May 2, 2001
Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemiaS L Soignet
The Oncologist|May 2, 2001
Risk/benefit profile of arsenic trioxideD M Rust, S L Soignet
Cancer Chemotherapy and Pharmacology|September 29, 1999
Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemiaS L Soignet, W P Tong, S Hirschfeld, et al.
Blood|August 15, 2000
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesisG J Roboz, S Dias, G Lam, et al.
Leukemia|October 10, 1998
Clinical study of 9-cis retinoic acid (LGD1057) in acute promyelocytic leukemiaS L Soignet, F Benedetti, A Fleischauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2000
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxideL H Camacho, S L Soignet, S Chanel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550)S L Soignet, V A Miller, D G Pfister, et al.
The New England Journal of Medicine|November 5, 1998
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxideS L Soignet, P Maslak, Z G Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2001
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemiaS L Soignet, S R Frankel, D Douer, et al.
Pageof 1